Investment report on Anadys Pharmaceuticals

Apr 16 2010

MicroStockProfit.com announces an investment report featuring Anadys Pharmaceuticals Inc. (Nasdaq:ANDS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ANDS

Anadys Pharmaceuticals Inc. (ANDS) is a biopharmaceutical company focused on developing medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C and ANA773. Both ANA598 and ANA773 were discovered at ANDS and are wholly owned assets of ANDS. With ANA598, the Company is focused on developing a direct antiviral, meaning a product candidate that acts by directly interacting with, and blocking the function of, a component of the virus. With ANA773, ANDS is stimulating the patient's own immune system to block cells infected with the hepatitis C virus from further amplifying the infection by producing more virus particles. 

In the report, the analyst notes:

"As of December 31, 2009, the Company's cash, cash equivalents and securities available-for-sale totaled $20.5 million compared to $27.9 million as of December 31, 2008. The decrease in cash, cash equivalents and securities available-for-sale is the result of ANDS' cash utilization to fund operations during 2009 partially offset by proceeds of approximately $16.0 million received from a "registered direct" offering of common stock and warrants in early June 2009. 

"ANDS announced recently that 72% of hepatitis C patients receiving ANA598 400 mg, twice daily (bid), plus standard of care (SOC), achieved undetectable levels of virus at week eight in an ongoing phase II study, compared to 38% of patients receiving placebo plus SOC. The preliminary analysis of results through eight weeks also showed that ANA598 400 mg bid plus SOC was well tolerated, with an adverse event profile comparable to SOC alone. As seen before at 200 mg bid, no patient experienced viral breakthrough on ANA598."